MANE Latest Headlines

Veradermics’ Phase 2/3 VDPHL01 Results Set for April 27—Could the First Oral Non-Hormonal Hair Loss Drug Be on the Horizon?

Market Chameleon (Mon, 27-Apr 10:29 AM)

Veradermics’ Oral VDPHL01 Demonstrates Significant Hair Growth and Superior Patient Outcomes in Phase 2/3 Trial

Market Chameleon (Mon, 27-Apr 7:51 AM)

Veradermics announces launch of public offering

at seekingalpha.com (Mon, 27-Apr 5:48 PM)

Buy Rating Reiterated as Strong VDPHL01 Data De-Risk Program and Drive Price Target Increase to $120

at www.tipranks.com (Mon, 27-Apr 2:45 PM)

Veradermics Reports Positive Phase 2/3 Data for VDPHL01

at www.tipranks.com (Mon, 27-Apr 9:32 AM)